-$0.95 Earnings Per Share Expected for MacroGenics Inc (MGNX) This Quarter

Share on StockTwits

Equities research analysts predict that MacroGenics Inc (NASDAQ:MGNX) will announce earnings per share (EPS) of ($0.95) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for MacroGenics’ earnings, with estimates ranging from ($1.27) to ($0.37). MacroGenics posted earnings of ($1.34) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 29.1%. The firm is expected to report its next earnings report on Monday, May 6th.

On average, analysts expect that MacroGenics will report full year earnings of ($3.75) per share for the current year, with EPS estimates ranging from ($5.18) to ($1.81). For the next year, analysts anticipate that the company will report earnings of ($4.20) per share, with EPS estimates ranging from ($5.49) to ($2.52). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow MacroGenics.

MGNX has been the subject of a number of research analyst reports. Raymond James reaffirmed a “sell” rating on shares of MacroGenics in a report on Monday, January 21st. ValuEngine raised MacroGenics from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 7th. Citigroup raised MacroGenics from a “sell” rating to a “buy” rating and lifted their price target for the company from $10.00 to $39.00 in a report on Thursday, February 7th. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price target (up from $34.00) on shares of MacroGenics in a report on Wednesday, February 6th. Finally, Nomura lifted their price target on MacroGenics from $41.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, February 7th. One analyst has rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $31.78.

Shares of NASDAQ MGNX traded up $0.08 during midday trading on Wednesday, reaching $17.49. 389,800 shares of the company traded hands, compared to its average volume of 1,339,385. The stock has a market cap of $856.44 million, a PE ratio of -4.17 and a beta of 2.99. MacroGenics has a 12 month low of $9.87 and a 12 month high of $32.32.

In related news, Director Matthew K. Fust sold 6,924 shares of MacroGenics stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $29.38, for a total value of $203,427.12. Following the completion of the sale, the director now directly owns 7,424 shares in the company, valued at $218,117.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Thomas Spitznagel sold 1,770 shares of MacroGenics stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $30.00, for a total value of $53,100.00. Following the completion of the sale, the senior vice president now owns 1,770 shares of the company’s stock, valued at $53,100. The disclosure for this sale can be found here. Insiders sold 8,762 shares of company stock valued at $258,567 over the last ninety days. 8.82% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in MGNX. Acadian Asset Management LLC acquired a new stake in MacroGenics in the fourth quarter worth about $65,000. Great West Life Assurance Co. Can increased its position in MacroGenics by 148.6% in the fourth quarter. Great West Life Assurance Co. Can now owns 6,215 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,715 shares during the period. Legal & General Group Plc increased its position in MacroGenics by 20.4% in the fourth quarter. Legal & General Group Plc now owns 7,432 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,261 shares during the period. Meeder Asset Management Inc. increased its position in MacroGenics by 4,851.9% in the fourth quarter. Meeder Asset Management Inc. now owns 12,033 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 11,790 shares during the period. Finally, Sun Life Financial INC increased its position in MacroGenics by 58.0% in the fourth quarter. Sun Life Financial INC now owns 12,947 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 4,751 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

See Also: Swap

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lions Gate Entertainment  Stock Rating Reaffirmed by Barrington Research
Lions Gate Entertainment Stock Rating Reaffirmed by Barrington Research
Ingredion  Raised to Hold at Zacks Investment Research
Ingredion Raised to Hold at Zacks Investment Research
Adviser Investments LLC Buys New Stake in Thermo Fisher Scientific Inc.
Adviser Investments LLC Buys New Stake in Thermo Fisher Scientific Inc.
Cosan Ltd  Position Boosted by Acadian Asset Management LLC
Cosan Ltd Position Boosted by Acadian Asset Management LLC
Aspen Technology, Inc.  Shares Sold by Acadian Asset Management LLC
Aspen Technology, Inc. Shares Sold by Acadian Asset Management LLC
10 15 Associates Inc. Invests $1.31 Million in VanEck Vectors Wide Moat ETF
10 15 Associates Inc. Invests $1.31 Million in VanEck Vectors Wide Moat ETF


© 2006-2019 Ticker Report